Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 36Recurrence 9Neoplasms, Plasma Cell 5Neoplasms 3Lymphoma, Non-Hodgkin 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Neoplasms 2Hematologic Diseases 2Blood Protein Disorders 2Thrombocythemia, Essential 1Sarcoma, Kaposi 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Polycythemia Vera 1Paraproteinemias 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Primary Effusion 1Leukemia, Myeloid, Acute 1Hypoxia 1Hodgkin Disease 1Corneal Diseases 1Carcinoma, Small Cell 1

Interventions

romidepsin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Vincristine 4Gemcitabine 4Doxorubicin 4Cyclophosphamide 4Prednisone 3Lenalidomide 3Azacitidine 310-propargyl-10-deazaaminopterin 3pembrolizumab 2ixazomib 2fludarabine phosphate 2copanlisib 2Whole-Body Irradiation 2Vitamin B 12 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mycophenolic Acid 2Folic Acid 2Etoposide 2Dexamethasone 2Cyclosporine 2Bortezomib 2venetoclax 1tislelizumab 1tazemetostat 1relatlimab 1prednisolone phosphate 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell, Peripheral × pomalidomide × Clear all
NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

CellCentric Ltd.

Phase 1/2 Recruiting
250 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡